KalVista Pharma rises as swelling disorder drug gets FDA approval

Kalvista Pharmaceuticals

07/07/2025 11:46

** Shares of drug developer KalVista Pharmaceuticals KALV.O rise 8.6% to $13.01 premarket

** Company says the U.S. FDA approved its drug for a type of hereditary swelling disorder in adult and pediatric patients aged 12 years and older

** Ekterly becomes the first on-demand oral treatment for hereditary angioedema, offering a convenient alternative to injectable treatments, company says

** Hereditary angioedema is a genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the limbs, face, intestinal tract, and airway caused by deficiency in a protein known as C1 inhibitor

** As of last close, stock up 41.44% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))